Work

A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3107

Authors: Shashank Deoghare, Rajender Kamboj, Chirag Shah, Ruchika Irene Dillu, Neelam Kardekar, Shraddha Ekhatpurkar, Prashant Bajpai

Institution: Lupin Pharmaceuticals (India)

Language: English

Topic: Cancer-related gene regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822695

Cites:

Cited by:

Related to: 10